IndraLab

Statements

Sorafenib inhibits MAP3K7. 5 / 5
2 | 3
tas
No evidence text available
22037378
tas
No evidence text available
19654408
reach
"TAK1 is considered a tumor suppressor in hepatocytes.36 However, signaling network topologies are different between hepatocytes and HCC cells, and specific changes to the connections involving MEKK1 and TAK1 in HCC have been observed.37 Furthermore, the major drug currently used in treating advanced HCC, the multikinase inhibitor sorafenib,10 was recently shown to inhibit TAK1 activity in keratinocytes.38 These data suggest that HCC may involve co-opting TAK1 signaling in later stages of disease progression."
27567007
reach
"However, the multikinase inhibitor sorafenib [XREF_BIBR], which has already been proven to be clinically effective in the treatment of various malignancies, inhibits MAP3K7 and may specifically target leukemias with low expression of MAP3K7 [XREF_BIBR, XREF_BIBR]."
29914415
reach
"In agreement with our in vitro data, sorafenib was demonstrated to potently inhibit TAK1 kinase activity (IC50 = 1.5 microM) (XREF_FIG)."
26677977